TORONTO—Moderna says upcoming clinical trials for its COVID-19 vaccine will include Canadian children. The company announced details of its Phase 2/3 study of COVID-19 earlier this week. It’s expected to involve 6,750 healthy pediatric participants aged six months to 12 years. Moderna says initial participants are based in the United States but that Canadian sites will be added as the trial progresses. The biotech company says it hasn’t yet chosen the Canadian sites, nor Canadian participants. The trial will evaluate the safety and effectiveness of two doses given 28 days apart. Participants will be followed for one year after the second vaccination. In addition to Moderna, Canada has approved vaccines by Pfizer-BioNTech and Oxford-AstraZeneca for adult use, although the Pfizer product can be used by people as young as 16. Dr. Caroline Quach of the National Advisory Committee on Immunization said Tuesday that she expected to see trial data from …